Daniel Rauch

4.8k total citations
53 papers, 1.1k citations indexed

About

Daniel Rauch is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Daniel Rauch has authored 53 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Daniel Rauch's work include Colorectal Cancer Treatments and Studies (17 papers), Cancer Treatment and Pharmacology (16 papers) and Lung Cancer Treatments and Mutations (15 papers). Daniel Rauch is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Cancer Treatment and Pharmacology (16 papers) and Lung Cancer Treatments and Mutations (15 papers). Daniel Rauch collaborates with scholars based in Switzerland, Italy and Hungary. Daniel Rauch's co-authors include Piercarlo Saletti, Markus Borner, Dieter Koeberle, Roger von Moos, A. Roth, Walter Mingrone, Doris Lanz, Miklos Pless, Thomas Ruhstaller and Peter Brauchli and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Daniel Rauch

52 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Rauch Switzerland	20	711	385	221	185	156	53	1.1k
Claudia Maggi Italy	21	873 1.2×	360 0.9×	259 1.2×	332 1.8×	157 1.0×	36	1.3k
B. Mirtsching United States	12	1.1k 1.6×	459 1.2×	131 0.6×	126 0.7×	131 0.8×	27	1.3k
Clara Montagut Spain	10	716 1.0×	229 0.6×	356 1.6×	131 0.7×	58 0.4×	13	934
M. Machiavelli Argentina	14	760 1.1×	255 0.7×	157 0.7×	188 1.0×	58 0.4×	32	1.0k
Shozo Mori Japan	11	288 0.4×	201 0.5×	140 0.6×	241 1.3×	139 0.9×	63	688
K. Park South Korea	13	664 0.9×	482 1.3×	201 0.9×	224 1.2×	39 0.3×	43	994
J. Lacava Argentina	13	630 0.9×	186 0.5×	160 0.7×	324 1.8×	294 1.9×	31	1.2k
Junning Cao China	16	553 0.8×	213 0.6×	94 0.4×	381 2.1×	141 0.9×	90	907
Emmanuelle Samalin France	16	562 0.8×	353 0.9×	201 0.9×	78 0.4×	87 0.6×	75	827
H.‐G. Mergenthaler Germany	12	543 0.8×	212 0.6×	105 0.5×	206 1.1×	134 0.9×	33	903

Countries citing papers authored by Daniel Rauch

Since Specialization

Citations

This map shows the geographic impact of Daniel Rauch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Rauch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Rauch more than expected).

Fields of papers citing papers by Daniel Rauch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Rauch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Rauch. The network helps show where Daniel Rauch may publish in the future.

Co-authorship network of co-authors of Daniel Rauch

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Rauch. A scholar is included among the top collaborators of Daniel Rauch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Rauch. Daniel Rauch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moccia, Alden A., Christian Taverna, Sämi Schär, et al.. (2020). Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Advances. 4(23). 5951–5957. 17 indexed citations

Rothschild, Sacha I., Daniel Betticher, Sandro Anchisi, et al.. (2019). Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. Cancer Chemotherapy and Pharmacology. 84(4). 881–889. 6 indexed citations

Deressa, Biniyam Tefera, et al.. (2019). Breast cancer care in northern Ethiopia – cross-sectional analysis. BMC Cancer. 19(1). 393–393. 29 indexed citations

Moos, Roger von, Hanne Hawle, Stefanie Hayoz, et al.. (2018). Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE). Annals of Oncology. 29. viii609–viii610. 4 indexed citations

Moos, Roger von, Dieter Koeberle, Stefanie Hayoz, et al.. (2017). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08). European Journal of Cancer. 89. 82–89. 20 indexed citations

Cinieri, Saverio, Arlene Chan, Kadri Altundağ, et al.. (2016). Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer. 17(2). 91–99.e1. 8 indexed citations

Koeberle, Dieter, Jean‐François Dufour, Gyula Demeter, et al.. (2016). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Annals of Oncology. 27(5). 856–861. 102 indexed citations

Novak, Urban, Behrouz Mansouri Taleghani, Gabriela M. Baerlocher, et al.. (2016). BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Annals of Hematology. 96(3). 421–429. 25 indexed citations

Gautschi, Oliver, Sacha I. Rothschild, Qiyu Li, et al.. (2016). Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clinical Lung Cancer. 18(3). 303–309. 9 indexed citations

10.

Mueller, Beatrice U., Sandra Keller, Katja Seipel, et al.. (2015). Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity. Leukemia & lymphoma. 57(5). 1122–1129. 8 indexed citations

11.

Koeberle, Dieter, Jean‐François Dufour, Gyula Demeter, et al.. (2014). Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).. Journal of Clinical Oncology. 32(15_suppl). 4099–4099. 3 indexed citations

12.

Arnold, A., Roland Giger, Daniel Rauch, et al.. (2013). Taxane-containing induction chemotherapy followed by definitive chemoradiotherapy. Strahlentherapie und Onkologie. 189(8). 618–624. 11 indexed citations

13.

Ghadjar, Pirus, et al.. (2012). Diagnosis and treatment outcomes for patients with lymphoma of the parotid gland. The Laryngoscope. 123(3). 662–669. 12 indexed citations

14.

Früh, Martin, Richard Cathomas, Marco Siano, et al.. (2012). Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08). Clinical Lung Cancer. 14(1). 34–39. 22 indexed citations

15.

Helbling, Daniel, G. Bodoky, Oliver Gautschi, et al.. (2012). Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Annals of Oncology. 24(3). 718–725. 59 indexed citations

16.

Borner, Markus, Dieter Koeberle, Roger von Moos, et al.. (2008). Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of Oncology. 19(7). 1288–1292. 108 indexed citations

17.

Rochlitz, Christoph, Walter Mingrone, Bernhard C. Pestalozzi, et al.. (2006). Efficacy and Tolerability of Capecitabine with Weekly Paclitaxel for Patients with Metastatic Breast Cancer: A Phase II Report of the SAKK. Oncology. 71(1-2). 54–60. 8 indexed citations

18.

Hess, Dagmar, Beat Thürlimann, Olivia Pagani, et al.. (2004). Capecitabine and vinorelbine in elderly patients (≥65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Annals of Oncology. 15(12). 1760–1765. 27 indexed citations

19.

Uhlmann, Catrina, Pierluigi Ballabeni, Peter Brauchli, et al.. (2004). Capecitabine with Weekly Paclitaxel for Advanced Breast Cancer: A Phase I Dose-Finding Trial. Oncology. 67(2). 117–122. 15 indexed citations

20.

Rauch, Daniel, Stefan Aebi, S. Pampallona, et al.. (2000). Activity of Gemcitabine and Continuous Infusion Fluorouracil in Advanced Pancreatic Cancer. Oncology. 60(1). 43–48. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact